Autopsy report · NCT03925428

Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas

“Other - Protocol moved to Disapproved”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

National Cancer Institute (NCI)

Sponsor type

US National Institutes of Health

Conditions

Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma; Ann Arbor Stage III T-Cell Non-Hodgkin Lymphoma; Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma; Ann Arbor Stage IV T-Cell Non-Hodgkin Lymphoma

Interventions

Entinostat; Molibresib

Participants

0

Trials that died the same way

• Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
  “Replaced by another protocol” (68% match in meaning)
• Nitric Oxide During Cardiopulmonary Bypass in Neonates to Reduce Risk of Acute Kidney Injury
  “revised and combined with another protocol” (67% match in meaning)
• RCT for Women With a Persisting Pregnancy of Unknown Location
  “A new protocol was written to replace this protocol.” (66% match in meaning)
• Adjunctive Treatment With Vitamin D3 in Patients With Active IBD
  “Protocol is being modified.” (64% match in meaning)
• Bacteriophage Therapy in Patients With Prosthetic Joint Infections
  “Changes to protocol design” (63% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.